methyl 4-(6-{4-[(methoxycarbonyl)amino]phenyl}-4-(morpholin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate

• ChemBase ID: 72602
• Molecular Formular: C24H29N7O5
• Molecular Mass: 495.53096
• Monoisotopic Mass: 495.22301706
• SMILES: c1c(ccc(c1)c1nc2c(c(n1)N1CCOCC1)cnn2C1CCN(CC1)C(=O)OC)NC(=O)OC
• Canonical SMILES: COC(=O)Nc1ccc(cc1)c1nc(N2CCOCC2)c2c(n1)n(nc2)C1CCN(CC1)C(=O)OC
• InChI: InChI=1S/C24H29N7O5/c1-34-23(32)26-17-5-3-16(4-6-17)20-27-21(29-11-13-36-14-12-29)19-15-25-31(22(19)28-20)18-7-9-30(10-8-18)24(33)35-2/h3-6,15,18H,7-14H2,1-2H3,(H,26,32)
• InChIKey: IMXHGCRIEAKIBU-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: methyl 4-(6-{4-[(methoxycarbonyl)amino]phenyl}-4-(morpholin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
• IUPAC Traditional name: methyl 4-(6-{4-[(methoxycarbonyl)amino]phenyl}-4-(morpholin-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
• Synonyms: 4-[6-[4-[(Methoxycarbonyl)amino]phenyl]-4-(4-morpholinyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylic Acid Methyl Ester; WYE-354; WYE 354; WYE-354

Database IDs

• CAS Number: 1062169-56-5
• PubChem SID: 162037527
• PubChem CID: 44219749

CALCULATED PROPERTIES

• Acid pKa: 12.800424
• H Acceptors: 8
• H Donor: 1
• LogD (pH = 5.5): 2.6181035
• LogD (pH = 7.4): 2.6181347
• Log P: 2.618137
• Molar Refractivity: 154.9662 cm^3
• Polarizability: 50.622982 Å^3
• Polar Surface Area: 123.94 Å^2
• Rotatable Bonds: 6
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO

Safety Information

• Storage Condition: -20°C

Pharmacology Properties

• Target: mTOR

Product Information

• Salt Data: Free Base

DETAILS

Selleck Chemicals - S1266

Research Area

• Description: Cancer

Biological Activity

• Description: WYE-354 is a potent, specific and ATP-competitive inhibitor of mTOR with IC50 of 5 nM.
• Targets: mTOR; PI3Kα; PI3Kγ
• IC50: 5 nM; 1.89 μM; 7.37 μM ^[1]
• In Vitro: WYE-354 also inhibits several PI3Ks at micromolar levels. In HEK293 cells, WYE-354 (0.2 μM–5 μM) effectively inhibits both mTORC1 and mTORC2. WYE-354 (0.3 μM–10 μM) significantly blocks mTOR signaling and Akt activation in U87MG and MDA361 cells. Furthermore, WYE-354 potently inhibits proliferation in tumor cell lines including MDA-MB-361, MDA-MB-231, MDA-MB-468, LNCap, A498, and HCT116, with IC50 values ranging from 0.28 μM to 2.3 μM. The apoptosis induced by WYE-354 is accompanied by G1 cell cycle arrest and caspases activation. ^[1]In endothelial HUVEC cells, WYE-354 (10 nM–1 μM) also inhibits both mTORC1 and mTORC2 signaling, as revealed by dephosphorylation of S6 ribosomal protein and Akt, respectively. Furthermore, WYE-354 (10 nM–1 μM) activates mitogen-activated protein kinase (MAPK) signaling, which may be due to its inhibition of mTORC1. ^[2]
• In Vivo: In a mice xenograft model of PTEN-null PC3MM2 tumor, WYE-354 (50 mg/kg) effectively inhibits mTOR signaling and tumor growth. ^[1]

Protocol

• Protocol: Kinase Assay ^[1]
• mTOR inhibitor assays: The assays are performed in 96-well plates for 2 hours at room temperature in 25 μL containing 6 nM Flag-TOR(3.5), 1 μM His6-S6K, and 100 μM ATP. The assays are performed and detected by DELFIA employing the Eu-phospho-p70S6K T389 antibody. For inhibitor versus ATP matrix competition, mTOR kinase reactions are carried out with varying concentrations of ATP (0, 25, 50 100, 200, 400, and 800 μM) in combination with varying concentrations of WYE-354. The assays contained 12 nM Flag-TOR(3.5), 1 μM His-S6K, and are incubated for 30 min. The assay results are similarly detected by DELFIA and processed for generation of double-reciprocal plots.
• Protocol: Cell Assay ^[1]
• Cell Lines: Tumor cell lines including MDA-MB-361, MDA-MB-231, MDA-MB-468, LNCap, DU145, A498, and HCT116
• Concentrations: 0–50 μM, dissolved in DMSO
• Incubation Time: 72 hours
• Methods: Cells are plated in 96-well plates at 1000 to 3000 cells per well for 24 hours, treated with DMSO or varying concentrations of WYE-354. Viable cell densities are determined 72 hours later by MTS assay employing a CellTiter 96 kit. The effect of each treatment is calculated as percent of control growth relative to the DMSO-treated cells grown in the same culture plate. Inhibitor dose response curves are plotted for determination of IC50 values.
• Protocol: Animal Study ^[1]
• Animal Models: Nude mice (BALB/c, nu/nu, female) bearing PC3MM2 xenograft
• Formulation: Dissolved in 5% ethanol, 5% polysorbate 80, 5% PEG-400
• Doses: 50 mg/kg
• Administration: Administered via intraperitoneal injection

References

• References: [1] Yu K, et al. Cancer Res, 2009, 69(15), 6232-6240.
• References: [2] Dormond-Meuwly A, et al. Biochem Biophys Res Commun, 2011, 407(4), 714-719.

Toronto Research Chemicals - W950000

A pyrazolopyrimidines derivative that is a potent and ATP-competitive mTOR inhibitor with much reduced activity against PI 3-Kα or PI 3-Kγ. WYE-354 is equally potent against mTORC1 and mTORC2 activities in HEK293 immune complex kinase assays using S6K and

REFERENCES

• Yu K, et al. Cancer Res, 2009, 69(15), 6232-6240.
• Dormond-Meuwly A, et al. Biochem Biophys Res Commun, 2011, 407(4), 714-719.
• Yu, K. et al.: Cancer Res., 69, 6232 (2009)
• Zask, A. et al.: J. Med. Chem., 52, 5-13 (2009)
• Dormind-Meuwly, A. et al.: Biochem. Biophys. Res. Comm., 407, 714 (2009)